Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells
Authors:
- 4 May 2022
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 43 (11) , 2917-2928
Abstract
Non-alcoholic fatty liver disease (NAFLD) is emerging as an epidemic risk factor for hepatocellular carcinoma (HCC). The progression of NAFLD to HCC is closely associated with paracrine communication among hepatic cells. Vascular endothelial growth factor A (VEGFA) plays a key role in NAFLD and HCC; however, the cellular communication of VEGFA in the pathological transition from NAFLD to HCC remains unclear. Here, we found that VEGFA elevation was considerably distributed in hepatocytes of clinical and murine NAFLD-HCC specimens. Notably, progression from NAFLD to HCC was attenuated in hepatocyte-specific deletion of Vegfa (VegfaΔhep) mice. Mechanistically, VEGFA activated human hepatic stellate cell (HSC) LX2 into a fibrogenic phenotype via VEGF-VEGFR signaling in fatty acid medium, and HSC activation was largely attenuated in VegfaΔhep mice during NAFLD-HCC progression. Additionally, a positive correlation between VEGFA and hepatic fibrosis was observed in the NAFLD-HCC cohort, but not in the HBV-HCC cohort. Moreover, LX2 cells could be activated by conditioned medium from NAFLD-derived organoids, but not from HBV livers, whereas this activation was blocked by a VEGFA antibody. In summary, our findings reveal that hepatocyte-derived VEGFA contributes to NAFLD-HCC development by activating HSCs and highlight the potential of precisely targeting hepatocytic VEGFA as a promising therapeutic strategy for NAFLD-HCC.Keywords
This publication has 34 references indexed in Scilit:
- Inhibition of matrix metalloproteinase‐9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cellsJournal of Pineal Research, 2013
- Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver diseaseCytokine, 2012
- Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver DiseaseArchives of Medical Research, 2011
- Could inflammatory markers help diagnose nonalcoholic steatohepatitis?European Journal of Gastroenterology & Hepatology, 2009
- Mechanisms of Disease Progression in Nonalcoholic Fatty Liver DiseaseSeminars in Liver Disease, 2008
- The role of adipokines in liver fibrosisPathophysiology, 2008
- Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1Journal of Hepatology, 2006
- From Fat to InflammationGastroenterology, 2006
- Interplay among cardiotrophin‐1, prostaglandins, and vascular endothelial growth factor in rat liver regeneration†Hepatology, 2005
- Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosisHepatology, 2002